Relationship of remnant cholesterol with body mass index in patients of myocardial infarction.
DOI:
https://doi.org/10.55958/jcvd.v19i3.149Keywords:
Myocardial Infarction, Body Mass Index, Remnant Cholesterol IndexAbstract
Background: Remnant cholesterol is not only a link in the chain between obesity and ischemic heart disease, but also a direct contributor to the risk of cardiovascular illness. Remaining cholesterol's potential to increase cardiovascular risk is gaining attention. Although observational and genetic data suggests that higher levels of residual cholesterol in triglyceride-rich lipoproteins are associated with an increased risk of ischemic heart disease, direct measurements have not been able to determine what proportion of plasma cholesterol is present in remnant particles. The focus of this study is to determine whether there is a correlation between body mass index and the quantity of cholesterol in the body after a heart attack.
Methodology: The study was conducted at Department of Cardiology, Punjab Institute of Cardiology, Lahore from October 20, 2020 to April 20, 2021. Total 100 patients with myocardial infarction were enrolled in the study. Blood samples were taken through a disposable syringe under aseptic measures. Then all the samples were sent to the laboratory of the hospital for assessment of cholesterol level. Reports were assessed and remnant cholesterol was calculated. All patients were assessed of BMI i.e. height and weight were measured with the help of a staff nurse. The information was put into SPSS v25.0 for statistical analysis. The association between body mass index and residual cholesterol was determined using Pearson's correlation coefficient. The cutoff for significance was set at 0.05.
Results: Total 100 patients with myocardial infarction were enrolled in the study. Gender distribution showed that 67(67.0%) were males while 33(33.0%) were females. The mean age of the patients was 50.53±14.90 years. The mean BMI of the patients was 29.83±4.33 kg/m2 and remnant cholesterol index as 40.07±11.99 mg/dl. There was a positive correlation between remnant cholesterol and body mass index with a Karl Pearson correlation coefficient of 0.654 with p-value 0.00001.
Conclusion: Myocardial infarction risk is increased across the board when residual cholesterol is high, regardless of body mass index. This data implies that even in lean individuals, remnant cholesterol poses a risk for myocardial infarction. There is a favourable relationship between BMI and residual cholesterol.
References
Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacology & therapeutics. 2014;141(3):358-67.
Oh B, Sung J, Chun S. Potentially modifiable blood triglyceride levels by the control of conventional risk factors. Lipids in Health and Disease 2019;18(1):222.
Nordestgaard BG, Nicholls SJ, Langsted A, Ray KK, Tybjærg-Hansen A. Advances in lipid-lowering therapy through gene-silencing technologies. Nature Reviews Cardiology. 2018;15(5):261-72.
Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, et al. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation 2018;138(8):770-81.
Varbo A, Freiberg JJ, Nordestgaard BG. Remnant cholesterol and myocardial infarction in normal weight, overweight, and obese individuals from the general population. Circulation. 2017;136(1):16332.
Zeng RX, Li S, Zhang MZ, Li XL, Zhu CG, Guo YL, et al. Remnant cholesterol predicts peri-procedural myocardial injury following percutaneous coronary intervention in poorly-controlled type 2 diabetes. J Cardiol. 2017;70(2):113-20.
Balling M, Langsted A, Afzal S, Varbo A, Davey Smith G, Nordestgaard BG. A third of non-fasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals. Atherosclerosis. 2019;286:97-104.
Varbo A, Freiberg JJ, Nordestgaard BG. Remnant cholesterol and myocardial infarction in normal weight, overweight, and obese individuals from the Copenhagen general population study. Clinical chemistry. 2018;64(1):219-30.
Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626–35.
Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547–63.
Shaikh M, Wootton R, Nordestgaard BG, Baskerville P, Lumley JS, La Ville AE, et al. Quantitative studies of transfer in vivo of low density, Sf 12– 60, and Sf 60 – 400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb. 1991;11:569–77.
Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intimainner media. Arterioscler Thromb Vasc Biol. 1995;15:534–42.
Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta. 2006;367:36–47.
Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92:1355–74.
Saraswathi V, Hasty AH. The role of lipolysis in mediating the proinflammatory effects of very low density lipoprotein in mouse peritoneal macrophages. J Lipid Res. 2006;47:1406–15.
Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol. 2011;31:1716–25.
Timpson NJ, Nordestgaard BG, Harbord RM, Zacho J, Frayling TM, Tybjaerg-Hansen A, Davey Smith G. C-reactive protein levels and body mass index: elucidating direction of causation through reciprocal Mendelian randomization. Int J Obes (Lond). 2011;35:300–8.
Varbo A, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128:1298–309.
Varbo A, Benn M, Davey Smith G, Timpson NJ, Tybjaerg Hansen A, Nordestgaard BG. Remnant cholesterol, lowdensity lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circ Res. 2015;116:665–73.
Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427–36.
Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–55.
Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405–18.
Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875–84.
Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.
